Specific Immunotherapy With Mannan-Conjugated Allergoids for HDM-Allergic Rhinitis/Rhinoconjunctivitis_MM09-SIT-069.
Prospective, Randomised, Double-blind, Placebo-controlled Multicentre Trial of Efficacy and Safety of D. Pteronyssinus/D. Farinae Mannan-conjugated Allergoids in Patients With Mite-allergic Rhinitis/Rhinoconjunctivitis.
The goal of this clinical trial is to learn whether EP-088_MM09 works to treat house dust mite allergy. It will also assess the treatment's safety. EP-088_MM09 contains modified house dust mite allergens called mannan-conjugated allergoids.
The study plans to include 250 participants aged 12 to 65 years. They will have persistent, moderate to severe nasal allergy symptoms, with or without eye symptoms. Participants may also have mild or moderate allergic asthma, provided it is controlled.
The main questions are:
- Does the treatment lower allergy symptoms and the need for symptom-relief medicines compared with a placebo?
- What medical problems or reactions occur during treatment?
Researchers will assess how well the treatment works using a score combining symptoms and medication use. The main assessment will cover four weeks after the treatment course.
Participants will be assigned by chance to receive either EP-088_MM09 or a placebo. They will have an equal chance of receiving either treatment. The placebo looks like EP-088_MM09 but contains no active ingredients. Neither participants nor study doctors will know which treatment each participant receives.
Each participant will be in the study for approximately 14 to 21 months.
Participants will:
- Attend one or two visits before starting treatment to check whether they can take part.
- Attend 12 treatment visits, approximately once a month, to receive injections under the skin. They will receive two injections at the first treatment visit and one at each later visit.
- Stay at the clinic for at least 30 minutes after each injection.
- Record symptoms and medication use daily during specified periods.
- Complete questionnaires about their symptoms and quality of life, and provide blood samples.
- Attend a final visit about one month after the last treatment visit.
Participants who are also sensitive to pollen may need a second visit before starting treatment. This is needed if their first visit falls during the relevant pollen season or within one month before or after it.
調査の概要
状態
状態
条件
条件
介入・治療
介入・治療
詳細な説明
The study consists of a screening/baseline phase, a treatment phase and a final follow-up assessment.
The screening/baseline phase establishes each participant's symptom burden and use of allergy medication before treatment begins. Participants will record this information in a diary during defined assessment periods before and during treatment.
For participants who are also sensitised to pollen, the timing of assessments is designed to limit the influence of pollen exposure on the evaluation of house dust mite allergy. An additional baseline visit may therefore be required, depending on when the initial visit occurs relative to the relevant pollen season. The final symptom and medication assessment period will also be scheduled outside that pollen season, according to protocol-defined timing requirements. These scheduling arrangements account for variation in the overall duration of participation.
During treatment, the study team will review diary completion, concomitant medication and participants' health. Participants will also complete questionnaires and provide blood samples at scheduled visits.
The final follow-up assessment will take place approximately one month after the last treatment visit. It will include review of the final diary entries, medication use and any ongoing medical problems.
研究の種類
研究の種類
入学 (推定)
入学
段階
段階
- フェーズ 3
連絡先と場所
研究連絡先
研究連絡先
- 名前:Raquel Caballero
- 電話番号:607600638
- メール:rcaballero@inmunotek.com
研究連絡先のバックアップ
- 名前:Marta Romero
- メール:mromero@inmunotek.com
研究場所
-
-
-
Alicante、スペイン、03015
- 募集
- Quriónsalud Alicante
-
コンタクト:
- Lucía Sánchez-Cendal González, MD
- 電話番号:674 822 960
- メール:lucia.sanchezg@quironsalud.es
-
主任研究者:
- Ángel Ferrer Torres, MD
-
Cadiz、スペイン、11008
- まだ募集していません
- HLA CM La Salud
-
主任研究者:
- Francisco Moreno, MD
-
コンタクト:
- Francisco Moreno, MD
- 電話番号:27666 956 225 301
- メール:mariabelen.dominguez@grupohla.com
-
副調査官:
- Mª Belén Domínguez Aguado, MD
-
Murcia、スペイン、30817
- まだ募集していません
- Hosp. Rafael Méndez de Lorca
-
副調査官:
- Yulia Petryk Petryk, MD
-
コンタクト:
- Polec Ricardo Cardona, MD
-
主任研究者:
- Polec Ricardo Cardona, MD
-
Málaga、スペイン、29011
- まだ募集していません
- Hospital Materno Infantil - Hospital Universitario Regional de Málaga
-
コンタクト:
- María Martín Garcia, MD
- 電話番号:951292229
- メール:eeccped.hrmal@ibima.eu
-
主任研究者:
- Candelaria Muñoz, MD
-
副調査官:
- Ana Prieto, MD
-
副調査官:
- Juan Díaz, MD
-
Málaga、スペイン、29016
- 積極的、募集していない
- H. Quriónsalud Malaga
-
Valencia、スペイン、46015
- まだ募集していません
- Hospital Ribera-Povisa
-
コンタクト:
- Paula Martín Garcia, MD
- 電話番号:1545 .+34 900830680
- メール:pmartin@riberacare.com
-
主任研究者:
- Carmen Mogío, MD
-
副調査官:
- Paula Padín Sobral, MD
-
副調査官:
- Diego Blanco Garcia-Granero., MD
-
Valencia、スペイン、46026
- 募集
- Hospital U. y Politécnico La Fe
-
コンタクト:
- Miguel Tortajada, MD
- 電話番号:961244000
- メール:fundacion_hgv@fihguv.es
-
主任研究者:
- Miguel Tortajada, MD
-
副調査官:
- Guillermo Uriós, MD
-
副調査官:
- Pablo Ferrer, MD
-
-
Alicante
-
Elche、Alicante、スペイン、03203
- まだ募集していません
- Hospital General U. de Elche
-
コンタクト:
- Ana Maciá Navarro, MD
- 電話番号:966 616850
- メール:ana.macia@fisabio.es
-
主任研究者:
- Antonio Ramón Sánchez, MD
-
-
Extremadura
-
Badajoz、Extremadura、スペイン、06001
- 積極的、募集していない
- Clinica Dermatología y Alergia
-
-
Gran Canaria
-
Las Palmas de Gran Canaria、Gran Canaria、スペイン、35916
- 積極的、募集していない
- Complejo Hospitalario Universitario Insular Materno-Infantil
-
-
-
-
-
Braga、ポルトガル、4710-243
- まだ募集していません
- Unidade Local de Saúde de Braga, EPE
-
コンタクト:
- Liliana Ferreira, MD
- 電話番号:+351925822 081
- メール:liliana.ferreira@ccabraga.org
-
主任研究者:
- Carmen Botelho, MD
-
副調査官:
- Raquel Gomes, MD
-
副調査官:
- Ana Margarida Mesquita, MD
-
Santarém、ポルトガル、2005-177
- まだ募集していません
- Unidade Local de Saúde da Lezíria
-
コンタクト:
- David David Pina Trincão, MD
- 電話番号:00351 243 300 200
- メール:ensaios.clinicos@ulsleziria.min-saude.pt
-
主任研究者:
- David David Pina Trincão, MD
-
-
Castelo Branco District
-
Covilha、Castelo Branco District、ポルトガル
- まだ募集していません
- Unidade Local de Saúde de Cova da Beira
-
コンタクト:
- Luís Taborda Barata, MD
- メール:taborda@ulscbeira.min-saude.pt
-
主任研究者:
- Luís Taborda Barata, MD
-
-
Faro District
-
Portimão、Faro District、ポルトガル、8000-386
- まだ募集していません
- Unidade Local de Saúde do Algarve, EPE
-
コンタクト:
- Alexandra Filipe, MD
- 電話番号:'+351961 900 354
- メール:alexandraf@chua.min-saude.pt
-
主任研究者:
- Natacha Lopes, MD
-
副調査官:
- Filipa Ribeiro, MD
-
副調査官:
- Maria João Paes, MD
-
-
Ilha de São Miguel
-
Ponta Delgada、Ilha de São Miguel、ポルトガル、9500-370
- まだ募集していません
- Hospital do Divino Espirito Santo
-
コンタクト:
- Manuela Menezes, MD
- 電話番号:+351 296 203 000
- メール:moura.ip.medeiros@azores.gov.pt
-
主任研究者:
- Rodrigo Alves, MD
-
副調査官:
- Ana Moreira, MD
-
副調査官:
- Miguel Paiva, MD
-
-
Lisbon District
-
Amadora、Lisbon District、ポルトガル
- まだ募集していません
- Unidade Local de Saúde Amadora Sintra, EPE
-
コンタクト:
- Josélia Monteiro
- 電話番号:+351 965 742 858
- メール:joseliamgpm@hotmail.com
-
主任研究者:
- Anna Sokolova, MD
-
-
参加基準
適格基準
適格基準
就学可能な年齢
健康ボランティアの受け入れ
受講資格のある性別
説明
Inclusion Criteria:
-
Subjects who have signed and dated Informed Consent Form (ICF).
-
Female or male aged 12 to 65 years, both included.
-
Subjects with confirmed clinical history of inhalation allergy with moderate-severe persistent rhinitis/ rhinoconjunctivitis according to the ARIA classification(1) of at least 1 year duration (treated with anti-allergic medication) with or without mild-moderate intermittent or persistent controlled asthma according to the definition of GINA 2023(2) caused by D. pteronyssinus and/or D. farinae. The asthma diagnosis will be valid up to 12 months prior to signing the informed consent.
-
Subjects with positive skin prick test to a standardized allergen extract of D. pteronyssinus and/or D. farinae. The wheal major diameter must be ≥ 5 mm and greater than or equal to the wheal major diameter of the positive control (histamine). The results will be valid up to 12 months prior to the signature of the informed consent.
-
Subjects with specific IgE against a complete extract of D. pteronyssinus and/or D. farinae or any of the molecular components of allergenic sources with a value ≥ 3.5 kU/L. The results will be valid up to 12 months prior to the signature of the informed consent.
-
Subjects shall preferably be monosensitised to the study allergens. In the case of subjects sensitised to other aeroallergens, only those with the following characteristics (results valid 12 months prior to signing the informed consent form) may be included in the study:
- Subjects with a positive skin prick test for Blomia tropicalis, and/or Lepidoglyphus destructor and/or other mites. The specific IgE value for these allergens must be ≤ 3.5 kU/L.
- Subjects with positive skin prick test for dander may be included, provided that they have occasional exposure and symptoms. Subjects with habitual exposure to dander or living with animals must have a negative prick test.
- Subjects sensitised (positive prick test) to one or more pollens who must carry out the first symptom and medication collection (after baseline visit (BV) or additional baseline visit (ABV)) and last symptom and medication collection period (after visit 12), according to the following conditions:
1. Both symptom and medication collection periods must be carried out outside the pollen season.
2. Both symptom and medication collection periods must start at least one month before and one month after the pollen season.
An individual assessment of each subject will be performed in conjunction with the pollen calendar established for each geographical region to check that symptom and medication collection can be carried out under the above conditions. If this is not possible, subjects cannot be included in the study.
7. Subjects with negative skin prick test for moulds. 8. Women of childbearing age (i.e., following menarche and until postmenopause, defined as no menses for 12 months without an alternative medical cause, or non-subject to permanent sterilisation methods, such as hysterectomy, bilateral salpingectomy, and bilateral oophorectomy) must confirm menarche and have a urine pregnancy test negative result before enrolling the study.
9. Women of childbearing age must commit to using a highly effective contraception method during the trial and up to 1 months after the end of the investigational medicinal product. Such methods include combined (estrogen and progestogen containing) hormonal, contraception associated with inhibition of ovulation (oral, intravaginal, or transdermal), progestogen-only hormonal contraception associated with inhibition of ovulation (oral, injectable, or implantable), intrauterine device (IUD), intrauterine hormone-releasing system (IUS), male condom, diaphragm used with spermicide, bilateral tubal occlusion, vasectomised partner, or sexual abstinence.
10. Subjects capable of complying with dosage regimen. 11. Subjects must record symptoms and medication consumption in an electronic diary via smartphone (preferably) or in a paper diary.
To be confirmed at visit 1 (V1)
Only subjects who meet the following criteria will be eligible for randomization:
12. Subjects with a rhinitis/rhinoconjunctivitis combined symptom and medication score (RCSMS) ≥ 2 out of 6, recorded for at least 10 days, corresponding to moderate-to-severe allergic rhinitis/rhinoconjunctivitis (See Section 6.2).
Exclusion Criteria:
- Subjects sensitised (positive prick test) to one or more pollens where the time interval between baseline visit (BV) and additional baseline visit (ABV) is more than 7 months.
- Subjects who have received previous immunotherapy to allergens under study (D. pteronyssinus and D. farinae) during the last 5 years or currently receiving immunotherapy with any other allergen.
- Subjects who have undergone any desensitisation process (e.g., oral immunotherapy [OIT], milk, or egg) except those in the maintenance phase since at least 12 months.
- Those cases in which allergen-specific immunotherapy (AIT) would be a contraindication according to the criteria of European Allergy and Clinical Immunology Immunotherapy Subcommittee.(3)
- Subjects with uncontrolled asthma, according to GINA 2023(2),asthma with poor symptom control (frequent symptoms or reliever use, activity limited by asthma, night waking due to asthma) and/or frequent exacerbations (≥2/year) requiring oral corticosteroids (OCS), or serious exacerbations (≥1/year) requiring hospitalization.
- Asthmatic subjects with forced expiratory volume in the first second (FEV1) <80% despite pharmacological treatment. The result shall be valid up to 12 months prior to signing of informed consent (See Section 9.2).
- Subjects with severe asthma, according to GINA 2023(2), on Step 4 or 5 treatment, who had poor symptom control and had good adherence and inhaler technique.
- Subjects on treatment with β-blockers, except those administered topically, or angiotensin-converting enzyme (ACE) inhibitors.
- Subjects on treatment with immunosuppressive (not including corticosteroids), except those administered topically, or biological drug.
- Subjects requiring regular treatment with systemic corticosteroids (oral or injectable) for the treatment of rhinitis/rhinoconjunctivitis and asthma. The regular use of topical, cutaneous, or inhaled corticosteroids for the treatment of the pathologies mentioned above and atopic dermatitis is permitted.
- Unstable subjects who have suffered a respiratory tract infection and/or asthma exacerbation within 4 weeks prior to the screening/baseline visit.
- Subjects who have suffered chronic urticaria, severe anaphylaxis, or family history of angioedema within 2 years prior to the screening/baseline visit.
- Subjects having any contraindication for the use of adrenaline (e.g., hyperthyroidism, heart disease, or hypertension) according to the investigator's criteria.
- Subjects with other severe disease not related asthma or rhinitis/rhinoconjunctivitis that could interfere in the study treatment or the follow-up (e.g., epilepsy or nephropathy) according to investigator's criteria.
- Subjects with uncontrolled autoimmune diseases (e.g., thyroiditis or lupus), tumoral diseases, or immunodeficiencies.
- Subjects that could not comply with the study protocol, according to investigator's criteria, or have a serious mental illness.
- Subjects with known allergy to any of the components of the investigational medicinal products (IMPs) other than study allergens.
- Subjects with lower respiratory tract diseases, different from asthma, as emphysema, bronchiectasis, or chronic obstructive pulmonary disease.
- Use of drugs that could interfere with skin prick test reactions (e.g., antihistamines) within the deadlines set out in the protocol (See Section 9.2).
- Subjects having any nasal condition (e.g., nasal polyp or non-allergic rhinitis) that could affect an appropriate evaluation of the efficacy and/or safety, according to investigator's criteria.
- Subjects who required regular treatment with antihistamines and/or corticosteroids (systemic - oral or injectable-, topical, cutaneous, or inhaled) for other purposes than alleviating symptoms of allergic rhinitis, except temporal use (≤ 15 days) for diseases including common colds.
- Breastfeeding or pregnant women.
- Subjects who are immediate family members of the investigator.
- Concurrent participation in other clinical trials or previous participation within 30 days prior to the screening/baseline visit.
- Subjects with history of serious systemic reactions, including food, Hymenoptera venom, drugs, etc.
- Subjects with controlled or uncontrolled cancer.
研究計画
研究はどのように設計されていますか?
デザインの詳細
- 主な目的:処理
- 割り当て:ランダム化
- 介入モデル:並列代入
- マスキング:4倍
アーム数
武器と介入
参加者グループ / アーム参加者グループ / アーム |
介入・治療介入・治療 |
|---|---|
|
実験的:mixture of Dermatophagoides (group 1)
Group 1 will receive subcutaneous EP-088-MM09 at a concentration of 3,000 mTU/mL. |
The composition of the active IMP (EP-088_MM09) is as follows:
|
|
プラセボコンパレーター:Placebo (group 2)
Group 2: will receive subcutaneous placebo, identical in composition to the active IMP, but without active ingredients. |
The composition of the placebo IMP is as follows: • Identical in composition to the active IMP, but without active ingredients. |
この研究は何を測定していますか?
主要な結果の測定
主要な結果の測定
結果測定 |
メジャーの説明 |
時間枠 |
|---|---|---|
|
Rhinitis/Rhinoconjunctivitis Combined Symptom and Medication Score (RCSMS) by means of the Subject's Diary
時間枠:Baseline Visit or Additional Baseline visit (2 weeks), visit 3 (2 weeks), visit 6 (2 weeks), visit 9 (2 weeks) and visit 12 (4 weeks)
|
The combination score of symptoms and medication required for symptom control in rhinitis/rhinoconjunctivitis for each subject during the trial will be obtained by means of the Subject's diary. RCSMS corresponds to the sum of Rhinitis/rhinoconjunctivitis Symptom Score (RSS) and Rhinitis/rhinoconjunctivitis Medication Score (RMS). The assessment criteria for each symptom shall be as follows:
The RSS will correspond to the sum of the six rhinitis/rhinoconjunctivitis symptoms (itchy/red eyes, watery eyes, sneezing, itchy nose, runny nose, blocked nose), divided by six: The final score will range from 0 to 3. RMS will correspond to the highest level of medication taken on this day. The final RMS score will range from 0 to 3. The daily RCSMS is calculated as RCSMS (0-6) = RSS (0-3) + RMS (0-3). |
Baseline Visit or Additional Baseline visit (2 weeks), visit 3 (2 weeks), visit 6 (2 weeks), visit 9 (2 weeks) and visit 12 (4 weeks)
|
二次結果の測定
二次結果の測定
結果測定 |
メジャーの説明 |
時間枠 |
|---|---|---|
|
Rhinitis/Rhinoconjunctivitis Symptom Score (RSS)
時間枠:Baseline Visit or Additional Baseline visit (2 weeks), visit 3 (2 weeks), visit 6 (2 weeks), visit 9 (2 weeks) and visit 12 (4 weeks)
|
The RSS will correspond to the sum of the six rhinitis/rhinoconjunctivitis (itchy/red eyes, watery eyes, sneezing, itchy nose, runny nose, blocked nose), symptoms divided by six: (SS1+SS2+SS3+SS4+SS5+SS6) /6. The final score will range from 0 to 3. The assessment criteria for each symptom shall be as follows:
The Rhinitis/Rhinoconjunctivitis Symptom Score (RSS) will be obtained throughout the different trial periods for each subject by means of the Subject's Diary. |
Baseline Visit or Additional Baseline visit (2 weeks), visit 3 (2 weeks), visit 6 (2 weeks), visit 9 (2 weeks) and visit 12 (4 weeks)
|
|
Rhinitis/Rhinoconjunctivitis Medication Score (RMS)
時間枠:Baseline Visit or Additional Baseline visit (2 weeks), visit 3 (2 weeks), visit 6 (2 weeks), visit 9 (2 weeks) and visit 12 (4 weeks)
|
RMS will correspond to the highest level of medication taken on this day. The final RMS score will range from 0 to 3. Medication to assess rhinitis/rhinoconjunctivitis:
The Rhinitis/Rhinoconjunctivitis Medication Score (RMS) will be obtained throughout the different trial periods for each subject by means of the Subject's Diary |
Baseline Visit or Additional Baseline visit (2 weeks), visit 3 (2 weeks), visit 6 (2 weeks), visit 9 (2 weeks) and visit 12 (4 weeks)
|
|
Asthma Combined Symptom and Medication Score (ACSMS)
時間枠:Baseline Visit or Additional Baseline visit (2 weeks), visit 3 (2 weeks), visit 6 (2 weeks), visit 9 (2 weeks) and visit 12 (4 weeks)
|
The Asthma-Combined Symptom and Medication Score (ACSMS) will be obtained throughout the different trial periods for each subject with asthma using the data from the Subject's Diary. The ACSMS will correspond to the sum of ASS and AMS and will be calculated as follows: ACSMS (0-6) = ASS (0-3) + AMS (0-3) The final score will range from 0 to 6 |
Baseline Visit or Additional Baseline visit (2 weeks), visit 3 (2 weeks), visit 6 (2 weeks), visit 9 (2 weeks) and visit 12 (4 weeks)
|
|
Asthma Symptom Score (ASS)
時間枠:Baseline Visit or Additional Baseline visit (2 weeks), visit 3 (2 weeks), visit 6 (2 weeks), visit 9 (2 weeks) and visit 12 (4 weeks)
|
The Asthma Symptom Score (ASS) will be obtained throughout the different trial periods (See Flow-chart in 9.1) for each subject with asthma by means of the Subject's Diary. Asthma symptoms are the following:
The endpoint for each symptom will be as follows:
|
Baseline Visit or Additional Baseline visit (2 weeks), visit 3 (2 weeks), visit 6 (2 weeks), visit 9 (2 weeks) and visit 12 (4 weeks)
|
|
Asthma Medication Score (AMS)
時間枠:Baseline Visit or Additional Baseline visit (2 weeks), visit 3 (2 weeks), visit 6 (2 weeks), visit 9 (2 weeks) and visit 12 (4 weeks)
|
The asthma medication will be scored based on the therapeutic step in which the drugs are included in the GEMA 5.0 and GINA 2023 guidelines. The scoring method is detailed in the article entitled "Combination of Allergic Asthma Symptom and Medication Scores in Allergen Immunotherapy Trials: A Proposal." In the present study, the asthma medication will be scored as follows:
|
Baseline Visit or Additional Baseline visit (2 weeks), visit 3 (2 weeks), visit 6 (2 weeks), visit 9 (2 weeks) and visit 12 (4 weeks)
|
|
Asthma and Rhinitis/Rhinoconjunctivitis Symptom Score (ARSS)
時間枠:Baseline Visit or Additional Baseline visit (2 weeks), visit 3 (2 weeks), visit 6 (2 weeks), visit 9 (2 weeks) and visit 12 (4 weeks)
|
The Asthma and Rhinitis/Rhinoconjunctivitis Symptom Score (ARSS) will be obtained throughout the different trial periods (See Flow-chart in 9.1) for each subject with asthma using the data from the Subject's Diary. The ARSS will correspond to the sum of RSS and ASS and will be calculated as follows: ARSS (0-6) = RSS (0-3) + ASS (0-3) The final score will range from 0 to 6. |
Baseline Visit or Additional Baseline visit (2 weeks), visit 3 (2 weeks), visit 6 (2 weeks), visit 9 (2 weeks) and visit 12 (4 weeks)
|
|
Asthma and Rhinitis/Rhinoconjunctivitis Medication Score (ARMS)
時間枠:Baseline Visit or Additional Baseline visit (2 weeks), visit 3 (2 weeks), visit 6 (2 weeks), visit 9 (2 weeks) and visit 12 (4 weeks)
|
The Asthma and Rhinitis/Rhinoconjunctivitis Medication Score (ARMS) will be obtained throughout the different trial periods (See Flow-chart in 9.1) for each subject with asthma using the data from the Subject's Diary. The ARMS will correspond to the sum of RMS and AMS and will be calculated as follows: ARMS (0-6) = RMS (0-3) + AMS (0-3) The final score will range from 0 to 6. |
Baseline Visit or Additional Baseline visit (2 weeks), visit 3 (2 weeks), visit 6 (2 weeks), visit 9 (2 weeks) and visit 12 (4 weeks)
|
|
Asthma and Rhinitis/Rhinoconjunctivitis Combined Symptom and Medication Score (ARCSMS)
時間枠:Baseline Visit or Additional Baseline visit (2 weeks), visit 3 (2 weeks), visit 6 (2 weeks), visit 9 (2 weeks) and visit 12 (4 weeks)
|
The Asthma and Rhinitis/Rhinoconjunctivitis Combined Symptom and Medication Score (ARCSMS) will be counted throughout the different trial periods (See Flow-chart in 9.1) for each subject with asthma using the data from the Subject's Diary. The ARCSMS will correspond to the sum of RCSMS and ACSMS and will be calculated as follows: ARCMS (0-12) = RCSMS (0-6) + ACSMS (0-6) The final score will range from 0 to 12. |
Baseline Visit or Additional Baseline visit (2 weeks), visit 3 (2 weeks), visit 6 (2 weeks), visit 9 (2 weeks) and visit 12 (4 weeks)
|
|
Asthma exacerbations
時間枠:From visit 1 to the end of treatment at 12 months
|
Time to first asthma exacerbation, number, duration, and severity |
From visit 1 to the end of treatment at 12 months
|
|
Immunological parameters in blood samples
時間枠:In Baseline Visit or Visit 1 and in the Final visit
|
Total IgE Specific IgE and IgG4 Specific IgE/Total IgE ratio Anti-Saccharomyces cerevisiae antibodies (ASCA) (IgA and IgG) |
In Baseline Visit or Visit 1 and in the Final visit
|
|
Allergen profiling (ALEX technique)
時間枠:At the end of the study
|
Allergen profiling assessed using the Allergy Explorer (ALEX) multiplex assay to determine sensitization patterns to allergen extracts and molecular allergen components. Results will be used to characterize participants' allergen sensitization profiles. |
At the end of the study
|
|
Asthma Quality of Life Questionnaire (AQLQ)
時間枠:Baseline Visit, Additional Baseline visit, visit 3, visit 6, visit 9 and visit 12
|
The Asthma Quality of Life Questionnaire (AQLQ) consists of 32 items and 4 domains (symptoms, activity limitations, emotional function, and environmental stimuli). Each item is scored from 1 ("severe impairment") to 7 ("no impairment"). This questionnaire shall be completed by the subject at BV (subjects no sensitised to pollens or sensitised to pollens who do not have to attend the ABV), ABV (subjects sensitised to pollens who have to attend this visit), V3, V6, V9, and V12. |
Baseline Visit, Additional Baseline visit, visit 3, visit 6, visit 9 and visit 12
|
|
Rhinoconjunctivitis Quality of Life Questionnaire (RQLQ)
時間枠:Baseline Visit, Additional Baseline visit, visit 3, visit 6, visit 9 and visit 12
|
The Rhinoconjunctivitis Quality of Life Questionnaire (RQLQ) consists of 28 items (questions) and 7 domains (Activities Limitation, Sleep Problems, Non-Nose/Eye Symptoms, Practical Problems, Nose Symptoms, Eye Symptoms and Emotional Function). The score for each item for all domains, except for the emotional function domain, ranges from 0 ("not troubled") to 6 ("extremely troubled"). The score for the emotional domain ranges from 0 ("Never") to 6 ("Always"). This questionnaire shall be completed by the subject at BV (subjects no sensitised to pollens or sensitised to pollens who do not have to attend the ABV), ABV (subjects sensitised to pollens who have to attend this visit), V3, V6, V9, and V12. |
Baseline Visit, Additional Baseline visit, visit 3, visit 6, visit 9 and visit 12
|
|
Asthma Control Questionnaire (GINA 2023)
時間枠:Baseline visit and visit 12
|
The Asthma Control Questionnaire (GINA 2023) consists of 4 questions. To assess symptom control, the investigator will ask about the following in the past four weeks: frequency of asthma symptoms (days per week), any night waking due to asthma or limitation of activity and, for patients using a SABA reliever, frequency of its use for relief of symptoms. The interpretation of the answered questions is as follows:
|
Baseline visit and visit 12
|
|
Visual Analogue Scale (VAS)
時間枠:Baseline Visit, Additional Baseline visit, visit 3, visit 6, visit 9 and visit 12
|
The visual analogue scale is a 10 cm straight line, where the left end means that the subject feels very well, and the right end means that the subject feels very bad.
|
Baseline Visit, Additional Baseline visit, visit 3, visit 6, visit 9 and visit 12
|
|
Consumption of health resources
時間枠:From enrollment to the end of treatment at 12 months
|
For each subject, the number of times during the study period that he/she has performed the following due to allergy symptoms shall be counted:
|
From enrollment to the end of treatment at 12 months
|
|
Safety parameters
時間枠:From enrollment to the end of treatment at 12 months
|
|
From enrollment to the end of treatment at 12 months
|
協力者と研究者
協力者
協力者
捜査官
捜査官
- スタディチェア:Miguel Tortajada、H. U. y Politécnico la Fe
研究記録日
主要日程の研究
研究開始 (実際)
研究開始
一次修了 (推定)
一次修了
研究の完了 (推定)
研究の完了
試験登録日
最初に提出
最初に提出
QC基準を満たした最初の提出物
QC基準を満たした最初の提出物
最初の投稿 (実際)
最初の投稿
学習記録の更新
投稿された最後の更新 (実際)
投稿された最後の更新
QC基準を満たした最後の更新が送信されました
QC基準を満たした最後の更新が送信されました
最終確認日
最終確認日
詳しくは
本研究に関する用語
その他の研究ID番号
その他の研究ID番号
- MM09-SIT-069
個々の参加者データ (IPD) の計画
個々の参加者データ (IPD) を共有する予定はありますか?
医薬品およびデバイス情報、研究文書
米国FDA規制医薬品の研究
米国FDA規制機器製品の研究
この情報は、Web サイト clinicaltrials.gov から変更なしで直接取得したものです。研究の詳細を変更、削除、または更新するリクエストがある場合は、register@clinicaltrials.gov。 までご連絡ください。 clinicaltrials.gov に変更が加えられるとすぐに、ウェブサイトでも自動的に更新されます。